4basebio PLC (AIM:4BB)

London flag London · Delayed Price · Currency is GBP · Price in GBX
550.00
0.00 (0.00%)
At close: Feb 27, 2026
-51.75%
Market Cap 85.13M
Revenue (ttm) 1.78M
Net Income (ttm) -14.41M
Shares Out 15.48M
EPS (ttm) -0.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19
Average Volume 2,406
Open 550.00
Previous Close 550.00
Day's Range 556.00 - 557.40
52-Week Range 520.00 - 1,220.00
Beta 0.84
RSI 27.37
Earnings Date May 22, 2026

About 4basebio

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5’ and 3’ ends for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA product for in vitro transcription processes for the production of mRNA for use in vaccine... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 110
Stock Exchange London Stock Exchange AIM
Ticker Symbol 4BB
Full Company Profile

Financial Performance

In 2024, 4basebio's revenue was 933,000, an increase of 84.39% compared to the previous year's 506,000. Losses were -12.33 million, 60.9% more than in 2023.

Financial Statements

News

4basebio Plc - Director Dealing

4basebio Plc - Director Dealing PR Newswire LONDON, United Kingdom, February 11 11 February 2026 4basebio PLC ("4basebio" or the "Company") Director Dealings Cambridge, UK, 11 February 2026 - 4bas...

18 days ago - Finanz Nachrichten

4basebio Plc - Leadership Changes

4basebio Plc - Leadership Changes PR Newswire LONDON, United Kingdom, February 10 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 59...

19 days ago - Finanz Nachrichten